BIOV · BioVersys AG
28.60
CHFUnlock stock Insights
Create a free account to unlock price targets, recommendations, and commentary.
Overview
Market Cap
Fr164.81M
PE
0.00
EV/EBITDA
N/A
DIV Yield
0%
Payout Ratio
0%
MQV Rating
5Very Weak
As at 18/09/2026 12:00:00 AM
Price Chart
Description
- All-Companies
- All-Consensus
- HALO 200
- HALO All
- HALO Consensus Value
- HALO Small
- Near Resistance
- Recent Earnings upgrade
- Recent Price downgrade
Key Fundamentals
EPS 3 yr Growth
N/A
EBITDA Margin
NaN%
Operating Cashflow
-SFr22m
Free Cash Flow Return
-41.50%
ROIC
-41.30%
Interest Coverage
-10.70
Quick Ratio
10.10
Performance
52 weeks range
Low 21.2 - 33.6
Trade Value (12mth)
US$23,442.00
1 week
6.04%
1 month
11.51%
YTD
18.57%
1 year
-9.65%
All time high
37.00
Additional Data
Shares Outstanding (Fully Diluted)
6m
HALO Sector
Healthcare
Next Company Report Date
31-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
CHF
Short Sell (% of issue)
0.00
Health Scores
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Very Weak
Momentum
Price
Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Neutral
Balance Sheet
Strong
Valuation
Value
Consensus
Yield
News & Announcements
No announcements available.
Key Stakeholders
| Name | Title |
| GSK Plc | Public Company |
| Marina von Schönau | Individual |
| Viavalor AG | Private Company |
| Marc Jaquet | Individual |
| Barrus AG | Private Company |
